A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)

Phase 3

Recruiting

• Conditions: Developmental and Epileptic Encephalopathy
• Interventions: Drug: LP352; Drug: Placebo

• Registration Number: NCT06719141
• Lead Sponsor: Longboard Pharmaceuticals

Brief Summary

This (DEEp OCEAN Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DEE. The study consists of 3 main phases: Screening, Titration period, Maintenance period, followed by a Taper period and Follow-Up. The total duration of the study will be approximately 24 months.

Detailed Description

Not available

Study Timeline

• Study Start: 2024-11-11
• Status Verified: 2024-12
• Study First Submitted: 2024-12-02
• Study First Submitted QC: 2024-12-02
• Last Update Submitted: 2024-12-02
• Study First Posted: 2024-12-05
• Last Update Posted: 2024-12-05
• Primary Completion: 2026-10
• Study Completion: 2026-11

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 320

Inclusion Criteria

• Participants who are characterized as having Lennox-Gastaut Syndrome (LGS) must fulfill all of the following criteria:

  • Onset of seizures at ≤8 years old
  • History of tonic/tonic-atonic seizures plus at least 1 of the following seizure type(s): atypical absence, atonic, myoclonic, focal impaired awareness, generalized tonic-clonic, nonconvulsive status epilepticus, or epileptic spasms
  • Presence of developmental plateauing or regression
  • History of electroencephalogram (EEG) showing generalized slow (<2.5 Hertz [Hz]) spike-and-wave complexes

• Participants who are characterized as having DEE (Other) must fulfill all of the following criteria:

  • Does not meet criteria for LGS
  • Onset of seizures at ≤5 years old
  • Presence of developmental plateauing or regression
  • History of multiple seizure types
  • History of interictal EEG background showing diffuse or multifocal slowing (with or without epileptiform activity)

• The participant has a current occurrence of at least 1 of the following countable motor seizure types: generalized tonic-clonic, tonic (bilateral), clonic (bilateral), atonic (bilateral) with truncal/leg involvement, focal motor (including hemiclonic), and focal to bilateral tonic-clonic.

• The participant has demonstrated an average of at least 4 countable motor seizures per month for each of the 3 months prior to Screening.

• The participant has been taking 1 to 4 antiseizure medications (ASMs) at a stable dose for at least 4 weeks prior to Screening.

• The participant, parent, or caregiver is willing and able (in the judgment of the investigator) to comply with completion of the diaries throughout the study.

• The participant must be willing and able to provide written informed consent; in instances where the participant is unable to provide consent, an appropriate legal representative.

Read More

Exclusion Criteria

• The participant has a diagnosis of Dravet Syndrome (DS) or has a mutation of the Sodium channel protein type 1 subunit alpha (SCN1A) gene consistent with DS.
• The participant has been admitted to a medical facility for treatment of status epilepticus requiring mechanical ventilation within 3 months prior to Screening.
• The participant has a neurodegenerative disorder as indicated by magnetic resonance imaging or genetic testing.
• The participant has an acquired lesion/injury unrelated to the primary etiology that could contribute as a secondary cause of seizures.
• The participant is receiving exclusionary medications.
• The participant has used of any cannabis product or cannabidiol that is not in oral solution/capsule/tablet form, not obtained from a government-approved dispensary, or contains ≥50% Delta-9-tetrahydrocannabinol (THC).
• The participant has unstable, clinically significant neurologic (other than the disease being studied; eg, recurrent strokes), psychiatric, cardiovascular (eg, pulmonary arterial hypertension, cardiac valvulopathy, orthostatic hypotension/tachycardia), pulmonary, hepatic, renal, metabolic, gastrointestinal, urologic, immunologic, hematopoietic, or endocrine disease or other abnormality which may impact the ability of the participant to participate or potentially confound the study results.
• The participant is unable or unwilling to comply with any of the study requirements or timelines.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
LP352	LP352	Participants will be titrated up to highest tolerated dose of LP352 during the Titration period (Visit 2 - Visit 5), followed by maintenance period (Visit 5 - Visit 8) and then taper/down titration period.
Placebo	Placebo	Placebo for LP352

Primary Outcome Measures

Name	Time	Method
Frequency Percent Change in Countable Motor Seizures During Treatment Compared to Baseline	Baseline and up to 15 Weeks	The percent change from Baseline in countable motor seizure frequency during Treatment will be calculated as countable motor seizure frequency during Treatment minus countable motor seizure frequency during Screening and divided by seizure frequency during Screening and multiplied by 100 where each seizure frequency will be based on number of seizures.

Secondary Outcome Measures

Name	Time	Method
Safety and Tolerability of LP352	Up to 21 Weeks	Safety and tolerability as measured by incidence and severity of Treatment Emergent Adverse Events (TEAEs), Serious Adverse events (SAEs), AEs leading to discontinuation and clinically significant changes in laboratory parameters (hematology, serum chemistry and Urinalysis), physical examination findings, vital signs, growth parameters (height and weight), 12-lead electrocardiograms (ECGs), Columbia-Suicide Severity Rating Scale (C-SSRS) responses, and Patient Health Questionnaire-9 (PHQ-9) total score and Question 9 score.
Percentage of participants with ≥ 50% Reduction in countable motor seizures during the Treatment compared to Baseline	Baseline and up to 15 Weeks
Frequency Percent Change in Countable Motor Seizures during Maintenance compared to Baseline	Baseline and up to 15 Weeks

Trial Locations

Locations (7)

Site Number - USA02; 🇺🇸 Gulf Breeze, Florida, United States

Site Number - USA05; 🇺🇸 Orlando, Florida, United States

Site Number - USA11; 🇺🇸 Tampa, Florida, United States

Site Number - USA09; 🇺🇸 Atlanta, Georgia, United States

Site Number - USA07; 🇺🇸 Bethesda, Maryland, United States

Site Number - USA10; 🇺🇸 Livingston, New Jersey, United States

Site Number - USA03; 🇺🇸 Tacoma, Washington, United States